Video

Were PCSK9 Inhibitors Overhyped?

Author(s):

Lauren Santye, Assistant Editor

Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses access to cholesterol-lowering PCSK9 inhibitors and whether the hype regarding the impact of these medications was overblown.

Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses access to cholesterol-lowering PCSK9 inhibitors and whether the hype regarding the impact of these medications was overblown.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Image Credit: shidlovski | stock.adobe.com
Related Content
Compression socks with edema therapy concept. Futuristic socks with glowing patterns showcasing foot anatomy.
September 17th 2025

FDA Approves Bumetanide Nasal Spray for Edema With Heart Failure, Hepatic and Renal Disease

Luke Halpern, Assistant Editor
Pharmacy Focus: Role of Pharmacists in Proper Inhaler Usage
September 17th 2025

Pharmacy Focus: Role of Pharmacists in Proper Inhaler Usage

Jennifer Griffin, PharmD, MS Luke Halpern, Assistant Editor
Atopic dermatitis. Red, itchy hands with blisters seen by a dermatologist
September 17th 2025

Amlitelimab Meaningfully Clears Skin in Moderate-to-Severe Atopic Dermatitis

Luke Halpern, Assistant Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
September 17th 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Pharmacist Spotlight: Luke Witkowski, PharmD
September 17th 2025

Pharmacist Spotlight: Luke Witkowski, PharmD

PT Staff Luke Witkowski, PharmD
Abstract 3d cells of human or animal. Science concept
September 17th 2025

Novel Conditioning Strategies Emerge in Gene Therapy, Leaving Busulfan—and Toxicities—Behind

Luke Halpern, Assistant Editor
© 2025 MJH Life Sciences

All rights reserved.